Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-pyrrolidinopentiophenone (α-PVP), also known as APA-01 and by several other code names and street names such as "flakka" or "gravel", is a synthetic stimulant of the cathinone class. It was developed in the 1960s and is chemically related to pyrovalerone; it is the ketone analog of prolintane. α-PVP acts primarily as a psychostimulant with effects similar to cocaine or amphetamines. Its mechanism involves inhibition of norepinephrine and dopamine reuptake transporters (NDRI), leading to increased concentrations of these neurotransmitters in synaptic clefts. The drug has been used recreationally for its euphoric and stimulating effects but is associated with significant adverse events including agitation, paranoia, hallucinations, tachycardia, hypertension, aggression, psychosis-like states and risk of overdose[2]. It has no approved medical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-pyrrolidinopentiophenone.